Enterprise Value

6.00B

Cash

355.5M

Avg Qtr Burn

-148.7M

Short % of Float

12.88%

Insider Ownership

13.23%

Institutional Own.

95.99%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Empaveli (systemic pegcetacoplan) (APL-2) Details
Paroxysmal nocturnal hemoglobinuria

Approved

Quarterly sales

SYFOVRE™(Intravitreal pegcetacoplan) Details
Geographic atrophy, Age-related macular degeneration

Approved

Quarterly sales

Systemic pegcetacoplan (APL-2) Details
C3 Glomerulopathy, Immune complex membranoproliferative glomerulonephritis

Phase 3

Data readout

Systemic pegcetacoplan (APL-2) Details
Hematopoietic stem cell transplantation thrombotic microangiopathies

Phase 2

Data readout

Systemic pegcetacoplan (APL-2) Details
Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy

Phase 2

Update

APL-3007 (small interfering RNA silencing C3) Details
Autoimmune disease, Inflammatory disease

Phase 1

Data readout

Intravenous APL-9 Details
ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies)

Failed

Discontinued

Failed

Discontinued

Systemic pegcetacoplan (APL-2) Details
Amyotrophic lateral sclerosis

Failed

Discontinued